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Abstract
This is the ﬁrst study concerning the molecular epidemiology of
group A streptococcus in Serbia and includes 145 isolates from
patients with various infections during the period 2001–2007.
The emm types, superantigen proﬁle and susceptibility pattern
were determined. Among 31 emm types identiﬁed, the most
prevalent were emm6, emm12, emm1, and emm58. All isolates
showed uniform antimicrobial susceptibility to all tested antibiot-
ics, with the exception of tetracycline and erythromycin (41%
and 0.7% resistant strains, respectively). Signiﬁcant heterogeneity
of emm types was found, with a high frequency of emm6 and
emm58, as well as a considerable prevalence of tetracycline
resistance, and a low level of macrolide resistance.
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Streptococcus pyogenes (group A streptococcus (GAS)) is a
common human pathogen that causes a variety of diseases,
which differ greatly in severity. An increase in the incidence
of severe GAS infection in the late 1980s [1] has prompted
surveillance studies of streptococcal diseases around the
world. A striking variation in emm type distribution in differ-
ent geographical regions has been observed [2,3]. In addition,
different clinical manifestations were related to particular
M/emm types [4,5]. Since there, there have been no available
studies concerning GAS epidemiology in Serbia; the aim here
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was to analyse, for the ﬁrst time, the emm type distribution,
superantigen proﬁle and susceptibility pattern among GAS
isolates from patients with various streptococcal infections in
this part of Europe.
A total of 145 GAS isolates, collected in the period from
2001 to 2007, were included in the study. On the basis of
the isolation site, the isolates were categorized into four
groups: pharyngitis (n = 81), skin and soft tissue (n = 52),
invasive (n = 7), and other infections (n = 5; two from the
vagina and vulva, and one from urine). In the skin and soft
tissue group, the isolates were from patients with impetigo
(n = 7), cellulitis (n = 25), and wound infections (n = 20).
The isolates originated from both hospitalized patients
(n = 39) and outpatients from different regions of Serbia,
representing 70% of its territory, and a proportional num-
ber of strains was randomly chosen from each region per
year, except for the invasive isolates, all of which were
included.
S. pyogenes was identiﬁed by the presence of b-haemolysis
on blood agar, bacitracin susceptibility, a positive pyrrolido-
nyl–arylamidase test result, and agglutination with group A
antisera (Slidex, Streptokit; bioMerieux, Marcy L’Etoile,
France). Sequencing of emm was performed using Podbielski
[6] primers as previously described. The obtained sequences
were aligned with those available at the CDC emm type data-
base at http://www.cdc.gov/ncidod/biotech/strep/strepindex.
htm. Streptococcal superantigens speA, speC, speF and ssa
were detected by PCR following a previously published
protocol [7].
Antimicrobial susceptibility testing was performed by disk
diffusion using penicillin, erythromycin, clindamycin, and
tetracycline. In addition, 99 isolates were tested by the broth
microdilution method [8], and 41 isolates were tested using
the Phoenix automated system (Becton Dickinson, Diagnos-
tic Systems, Sparks, MD, USA) with the SMIC 10 panel. Pen-
icillin, amoxycillin, cefotaxime, clindamycin, tetracycline,
telithromycin, levoﬂoxacin, chloramphenicol and vancomycin
were used in both antimicrobial susceptibility testing systems;
clarithromycin and gatiﬂoxacin were used in the broth mic-
rodilution test rather than erythromycin and moxiﬂoxacin,
which were used in the Phoenix automated system. The
results were interpreted according to CLSI recommenda-
tions [8]. The study results were analysed by chi-square test,
and a p-value <0.05 was considered to be statistically
signiﬁcant.
A total of 31 different emm types were identiﬁed among
the 145 isolates tested (Table 1). The most prevalent types
were emm6 (13%), emm12 (13%), emm1 (12%), emm58
(11%), emm3 (8%), and emm4 (8%). No striking difference in
emm type distribution over the years of the surveillance per-
iod was observed (data not shown). Our results show a
higher heterogeneity of GAS types in Serbia than what has
been found in other European countries [9–12]. A factor
that possibly contributed to the higher diversity in our study
is the greater number of infection sites used for sampling. In
view of this, statistical analysis showed signiﬁcant differences
in the frequency of particular emm types between throat and
skin isolates. Whereas emm1, emm6 and emm12 were more
prevalent in the throat (p 0.006, p 0.003, and p 0.018,
respectively), emm58 was signiﬁcantly more frequent among
skin isolates (p <0.01). This is in line with previous reports
indicating the predilection of certain strains to cause skin or
throat infections [4]. In the pharyngitis isolate group, emm6
was the most prevalent type, whereas emm58 dominated the
skin isolate group. Although some studies reported a higher
frequency of emm6 [10], it was rarely found among dominant
emm types in pharyngitis patients [11]. Similarly, a high prev-
alence of emm58 among skin isolates has been reported in
the Far East [13], but not in Europe [10]. Thus, our results
imply a possible difference in the epidemiology of GAS in
Serbia.
Superantigen distribution (Table 2) showed that the over-
all incidences of speA, ssa and speC were 40%, 29%, and
42%, respectively. With respect to the isolation site, compa-
rable frequencies of superantigens were found in all groups
of isolates. Although the distribution of speA, ssa and speC
was previously reported to be variable [14,15], the associa-
tion of superantigens with certain emm types, such as emm1
and speA, has been found [16], as also observed in our
study.
Considering antimicrobial susceptibility, no resistance was
observed among isolates, except to tetracycline and erythro-
mycin. Tetracycline resistance was found in 41% of isolates
TABLE 1. Distribution of emm types among group A strep-
tococcus isolates fromdifferent sites
emm Type
Throat,
N (%)
Skin and
soft tissue,
N (%)
Invasive,
N (%)
Other,
N (%)
Total,
N (%)
6 18 (22) 1 (2) 19 (13)
12 16 (20) 2 (4) 1 (14) 19 (13)
1 16 (20) 1 (2) 1 (14) 18 (12)
58 2 (2) 12 (23) 1 (14) 1 (20) 16 (11)
3 10 (12) 1 (2) 11 (8)
4 7 (9) 3 (6) 1 (20) 11 (8)
50 1 (1) 5 (9) 1 (20) 7 (5)
28 4 (5) 1 (2) 1 (20) 6 (4)
53 3 (6) 1 (14) 4 (3)
82 4 (7) 4 (3)
Othera 7 (9) 19 (37) 3 (44) 1 (20) 30 (20)
Total 81 (100) 52 (100) 7 (100) 5 (100) 145 (100)
aemm Types with frequencies £3: emm22, emm33, emm52, emm66, emm68,
emm75, emm76, emm77, emm78, emm85, emm87, emm88, emm89, emm90,
emm92, emm94, emm95, emm101, emm109, emm117, emm118.
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and among 20 different emm types, indicating that the genes
encoding it could be acquired by a variety of GAS types. The
most prevalent types exhibiting this resistance were emm58,
emm12, emm53, emm82, and emm85. A correlation between
resistance and a particular emm type was observed; emm58
isolates were uniformly resistant to tetracycline, whereas all
emm6 and emm1 isolates, except for one, were tetracycline-
susceptible. Overall, 70% of all skin isolates were resistant to
tetracycline, as compared to 24% of pharyngitis isolates
(p <0.01). On the other hand, erythromycin resistance was
found in only one isolate of the emm77 type (0.7% of all
isolates), which exhibited inducible macrolide–lincosamide–
streptogramin B resistance together with tetracycline resis-
tance. The low prevalence of macrolide resistance and the
high prevalence of tetracycline resistance, with extensive dis-
tribution of tetracycline-resistant strains, has already been
reported in different regions in the world [17,18], although
data from European countries imply the opposite [12,19,20].
The likely explanation for the observed discrepancy could be
the low level of macrolide use for the treatment of GAS
infections in Serbia. Regarding tetracyclines, although these
agents are not recommended for the treatment of GAS
infections, they were widely used in treating veterinary infec-
tions and in the poultry industry, indicating a possibly high
level of consumption.
In conclusion, this study is the ﬁrst report of emm type
distribution in Serbia, and underscores the difference in GAS
epidemiology between this region and other European
regions. In order to better understand the geographical and
time variations of GAS epidemiology in Serbia, further stud-
ies focusing on invasive isolates are planned.
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Abstract
This study was prospectively conducted in 11 haematology divi-
sions over a 2-year period to evaluate the efﬁcacy of caspofungin
in 24 neutropenic patients with haematological malignancies (HM)
and candidaemia. These patients had received chemotherapy for
HM and were neutropenic (PNN < 0.5 · 109/L) for a median of
12 days (2–41) before candidaemia. The patients received caspo-
fungin for a median duration of 12 days (range 6–26), obtaining a
favourable overall response of 58%. At 30 days, 11 patients had
died (46%); candidaemia was responsible for mortality in six
patients (25%). These results suggest that treatment of candida-
emia with caspofungin in neutropenic HM was efﬁcacious, as it is
in non-haematological subgroups.
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